- Coordinator
- Universitaetsklinikum Hamburg-Eppendorf, Germany
- Runs
- 1 May 2023 to 30 April 2028
- Status
- Running
- EU funding
- €17.7m
- Total cost
- €34.4m
- Partners
- 35 organisations in 13 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101112066
What the project is doing
In the project's own words, from its summary on CORDIS.
Advancing personalized approaches in cancer therapy, aiding identification and adaptation of multi-modal treatment strategies for improved outcomes depends on clinical implementation of novel diagnostic technologies. For most cancer types the risk-features used to select individuals for post-operative adjuvant multimodal therapy are suboptimal, where many patients are overtreated and others undertreated. Liquid biopsy has opened a new diagnostic avenue to detect and monitor minimal residual disease (MRD) in individual cancer patients, especially for selecting patients for multi-modal therapies post-operatively.
However, despite many circulating tumor DNA (ctDNA) diagnostics being developed there is a lack of standardization, harmonization, and robust data to demonstrate clinical validity. GUIDE.MRD is a consortium of leading academics, technology companies, pharmaceutical companies, and experts in multi-stakeholder engagements. Together, we will tackle the critical questions by developing reference standards for ctDNA diagnostics, clinically validate promising ctDNA diagnostics and develop data to guide the use of multi-modal therapies with a non-invasive diagnostic test.
With robust engagement with regulatory authorities, payers and importantly patients themselves, we will develop recommendations and guidelines based on objective data to use ctDNA diagnostics to guide multi-modal therapy selection to improve patient outcomes.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universitaetsklinikum Hamburg-Eppendorf | Hamburg | Germany | Coordinator |
| Medizinische Universitat Graz | Graz | Austria | Participant |
| Digestive Cancers Europe Dice | Bruxelles / Brussel | Belgium | Participant |
| Synergist Services | Bruxelles / Brussel | Belgium | Participant |
| The Synergist | Bruxelles / Brussel | Belgium | Participant |
| Amgen (europe) GmbH | Zug | Switzerland | Participant |
| F. Hoffmann-La Roche AG | Basel | Switzerland | Participant |
| Lung Cancer Europe Luce | Bern | Switzerland | Associatedpartner |
| Abbvie Deutschland GmbH & Co Kg | Wiesbaden | Germany | Associatedpartner |
| Bristol-Myers Squibb GmbH & Co. Kgaa | Munich | Germany | Associatedpartner |
| Lungenclinic Grosshansdorf GmbH | Grosshansdorf | Germany | Participant |
| Aarhus Universitet | Aarhus C | Denmark | Participant |
| Aarhus Universitetshospital | Aarhus | Denmark | Participant |
| Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncologicas Carlos Iii | Madrid | Spain | Participant |
| Bristol-Myers Squibb SAS | Rueil-Malmaison | France | Associatedpartner |
| Centre Hospitalier Universitaire De Nice | Nice | France | Participant |
| Centre Hospitalier Universitaire Montpellier | Montpellier | France | Participant |
| Innovation Acta SRL | Siena | Italy | Participant |
| Academisch Ziekenhuis Groningen | Groningen | Netherlands | Participant |
| Bristol-Myers Squibb B.V. | Utrecht | Netherlands | Associatedpartner |
| Asociatia Centrul Pentru Inovatie in Medicina | Bucharest | Romania | Participant |
| Karolinska Institutet | Stockholm | Sweden | Participant |
| Region Stockholm | Stockholm | Sweden | Participant |
| Astrazeneca UK Limited | Cambridge | United Kingdom | Participant |
| Horizon Discovery Limited | Cambridge | United Kingdom | Participant |
| Illumina Cambridge Limited | Cambridge | United Kingdom | Participant |
| Labcorp Early Development Laboratories Limited | Harrogate | United Kingdom | Participant |
| Abbvie Inc | North Chicago Il | United States | Participant |
| Amgen Inc | Newbury Park | United States | Associatedpartner |
| AstraZeneca Pharmaceuticals LP | Wilmington | United States | Associatedpartner |
| Bristol-Myers Squibb Company Corp | New York | United States | Participant |
| E.r. Squibb & Sons Llc | New Brunswick | United States | Associatedpartner |
| Illumina Inc. | San Diego | United States | Associatedpartner |
| Lgc Clinical Diagnostics Inc | Milford | United States | Participant |
| Personal Genome Diagnostics Inc. | Baltimore | United States | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI